Up to now, TREM2 has been developed as a potential target for Alzheimer’s disease, solid tumors and other diseases, although no drug targeting TREM2 has been approved, many pharmaceutical companies have laid out the research pipeline of targeting TREM2, and our findings will also further accelerate the clinical translation and application of therapies targeting TREM2. The gene discussed is TREM2; the disease is early-onset autosomal dominant Alzheimer disease.